He Zhang

Dr. He Zhang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2022 in Hepatology Communications
Verified
Journal Article
Open access
DQDingding Qu
Dingding Qu
YWYi Wang
Yi Wang
QXQingxin Xia
Qingxin Xia
JCJing Chang
Jing Chang
XJXiangnan Jiang
Xiangnan Jiang
HZHe Zhang
He Zhang
Primary liver tumors (PLCs) and liver metastasis currently represent the leading cause of cancer‐related deaths worldwide due to poor outcomes, high incidence, and postsurgical recurrence. Hence, novel diagnostic markers and therapeutic strategies for PLCs are urgently needed. The human microbiome can directly or indirectly impact cancer initiation, progression, and response to therapy, including cancer immunotherapy; however, the roles of the microbiota in the tumor microenvironment are not clear and require more investigation. Here, we investigated intratumoral microbial community profiling on formalin‐fixed paraffin‐embedded tissue samples of patients with PLC by 16S ribosomal RNA using the MiSeq platform. We characterized the microbial communities in different histopathological subtypes and in the different prognoses of patients with PLC. The study revealed microbial population differences not only in carcinoma tissue and the matched adjacent nontumor tissue but in different histopathological subtypes, even in patients with PLC with different prognoses. Interestingly, the abundance of certain bacteria that have antitumor effects at family and genus level, such as Pseudomonadaceae, decreased in tumor tissue and was linearly associated with prognosis of patients with PLC. Conclusion: We provide a potential novel diagnostic biomarker and therapeutic strategy for early clinical diagnosis and treatment of PLC.

12 October 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
YWYi Wang
Yi Wang
DQDingding Qu
Dingding Qu
YZYali Zhang
Yali Zhang
YJYiping Jin
Yiping Jin
YFYu Feng
Yu Feng
QXQingxin Xia
Qingxin Xia
Triple-negative breast cancer (TNBC) presents significant challenges to female health owing to the lack of therapeutic targets and its poor prognosis. In recent years, in the field of molecular pathology, there has been a growing focus on the role of intra-tumoral microbial communities and metabolic alterations in tumor cells. However, the precise mechanism through which microbiota and their metabolites influence TNBC remains unclear and warrants further investigation. In this study, we analyzed the microbial community composition in various subtypes of breast cancer through 16S rRNA MiSeq sequencing of formalin-fixed, paraffin-embedded (FFPE) tissue samples. Notably, Turicibacter, a microbe associated with cancer response, exhibited a significantly higher abundance in TNBC. Similarly, mass spectrometry-based metabolomic analysis revealed substantial differences in specific metabolites, such as nutriacholic, pregnanetriol, and cortol. Furthermore, we observed significant correlations between the intra-tumoral microbiome, clinicopathological characteristics, and human epidermal growth factor receptor-2 expression(HER2). Three microbial taxa (Cytophagaceae, Conexibacteraceae, and Flavobacteriaceae) were associated with tumor-infiltrating lymphocytes(TILs), which are indicative of antitumor immunity. This study creatively utilized FFPE tissue samples to assess intra-tumoral microbial communities and their related metabolic correlations, presenting avenues for the identification of novel diagnostic biomarkers, the development of therapeutic strategies, and the early clinical diagnosis of TNBC.

19 May 2023 in Heliyon
Verified
Journal Article
Open access
JCJing Chang
Jing Chang
XLXiang Li
Xiang Li
QXQingxin Xia
Qingxin Xia
SYShumin Yang
Shumin Yang
HZHe Zhang
He Zhang
HYHui Yang
Hui Yang
Breast cancer (BC) tissues have been proved to harbor microorganisms, which could potentially contribute to oncogenesis. Formalin-fixed paraffin-embedded (FFPE) tissues are the most widespread clinical samples in BC research. To verify the potential of FFPE tissues in microbiological analysis, we analyzed the microbial communities of FFPE and fresh frozen (FF) tumor samples from 30 participants diagnosed with BC deploying 16S rRNA sequencing. The operational taxonomic units (OTUs) analysis showed that 78.55% of OTUs in FFPE samples were consistent with FF samples. The composition of core bacteria did not change much, and there is also no difference in alpha diversity between FFPE and FF (without unclassified bacteria). Taxonomic variation results show that Firmicutes and Bacteroidota phyla, and their major classes, maintained the same proportion under two preservation methods. In addition, the major class Gammaproteobacteria, as well as its dominant orders Burkholderiales and Pseudomonadales all showed no significant difference in paired analysis. Moreover, the Proteobacteria and Actinobacteriota phyla showed no significant difference between FFPE and FF samples after subtracting unclassified bacteria. Therefore, premised with the intrinsic tumor heterogeneity and unclassified bacteria, there are potential values of FFPE tissues for intratumoral microbiome analysis in breast cancer.

1 January 2025 in American Journal of Cancer Research
Verified
Journal Article
Closed access
XSXu Sun
Xu Sun
XMXiaona Meng
Xiaona Meng
QWQike Wang
Qike Wang
LZLu Zhang
Lu Zhang
XYXiaolin Yu
Xiaolin Yu
HLHuaimin Liu
Huaimin Liu
Objectives: To characterize the clinical features of non-small cell lung cancer (NSCLC) harboring BRAF mutations and to evaluate the effects of first-line chemotherapy combined with immunotherapy versus targeted therapy. Methods: We retrospectively reviewed patients with BRAF-mutated NSCLC diagnosed between January 2017 and June 2023 at the Affiliated Cancer Hospital of Zhengzhou University. A total of 120 patients were included, with an overall BRAF mutation frequency of 0.9%. Among the mutations detected, the Val600Glu (V600E) substitution constituted 54.2% of cases. Clinical characteristics were compared between V600E and non-V600E subgroups, and treatment efficacies were analyzed. Results: Ninety-five patients received first-line treatment. The overall median progression-free survival (mPFS) was 8.77 months, and the median overall survival (mOS) was 13.30 months. First-line chemotherapy combined with immunotherapy resulted in longer mPFS (17.17 vs. 9.03 months, P = 0.573) and mOS (17.50 vs. 16.07 months, P = 0.376) compared with targeted therapy using BRAF and MEK inhibitors. In addition, patients with V600E mutations exhibited a trend toward longer mPFS compared to those with non-V600E mutations (9.73 vs. 6.77 months, P = 0.244). Conclusions: Chemotherapy combined with immunotherapy may represent a promising first-line treatment strategy for NSCLC patients with BRAF mutations. Although the number of patients receiving subsequent lines of treatment was limited and their prognosis poor, a regimen of BRAF and MEK inhibitors appeared to offer therapeutic advantages in this setting.

10 March 2023
Verified
Preprint
Open access
PDF file
BRBeibei Ren
Beibei Ren
YCYu Chen
Yu Chen
XBXuanye Bai
Xuanye Bai
JZJiawen Zheng
Jiawen Zheng
JCJing Chang
Jing Chang
HZHe Zhang
He Zhang
Pediatric follicular lymphoma (PTFL) is one of the rare pediatric-type indolent B-cell lymphomas that clinicopathologically differs from adult lymphoma. Accurate diagnosis of PTFL is essential to avoid leak-diagnosis, misdiagnosis and overtreatment, but it is often challenging. To improve the understanding of PTFL, we collected four cases of PTFL, and analyzed the clinicopathological features, differential diagnosis and molecular mutation characteristics of PTFL by hematoxylin‑eosin stain, immunohistochemistry, polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH) and Next Generation Sequencing (NGS). The relevant literature review was also performed. Four PTFL patients were all male, aged 6, 18, 13 and 15 years, and St. Jude were staged III. and I.. Microscopic results showed that the lymph node structure was destroyed; the tumor follicles were enlarged and irregular; medium-large blast-like cells with a consistent shape were visible in tumor follicles, and the nucleus was round or oval; the “starry sky” phenomenon was easy to discover. Tumor cells expressed CD20, PAX-5, Bcl-6, CD10. None of the tumor cells expressed Bcl-2, CD3, CD5, MUM-1, and CyclinD1. CD21 showed dilated growth of follicular dendritic cell (FDC) mesh in tumor follicles. EBER were all negative. FISH testing also showed negative Bcl-2 gene breaks in four cases. A total of 12 related mutant genes including KMT2D , CD79B , GNA13 , MYD88 , PCLO , TCF3 , IRF8 , MAP2K1 , FOXO1, POLE, INPP5D and FAT4 were detected by NGS. Two of the four cases had IRF8 gene mutation, and one case detected a dual mutation of the MAP2K1 gene. Our data reviewed the unique clinicopathological features and molecular mutational characteristics of PTFL, consolidated the understanding of PTFL, and identified other rare mutant genes, which may further contribute to the study of the molecular mechanism and differential diagnosis of PTFL.

2 July 2025 in Cytojournal
Verified
Journal Article
Open access
BRBeibei Ren
Beibei Ren
BZBing Zhang
Bing Zhang
XJXiangnan Jiang
Xiangnan Jiang
HZHe Zhang
He Zhang
QXQingxin Xia
Qingxin Xia
Metaplastic breast carcinoma comprises a heterogeneous group of morphologic variants characterized by markedly aggressive pathological behavior and diverse histological subtypes. Accurate diagnosis of metaplastic breast carcinoma is essential for implementing effective and individualized treatment approaches; however, its differentiation from similar tumors may occasionally be challenging. We report two cases of breast tumors diagnosed using comprehensive tumor genome analysis.